Physician profile
Michael G Stone
NPI 1396078226
$543.63
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $328 · 2022: $37.67 · 2023: $178.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $178.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $178.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $192.75 | 2019-2023 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $63.39 | 2019 | |
| Pfizer INC. | $45.17 | 2019 | |
| Novo Nordisk INC | $39.49 | 2019-2023 | Ozempic, Rybelsus |
| Roche Diagnostics Corporation | $35.40 | 2019 | |
| Lilly USA, LLC | $33.91 | 2019-2022 | |
| Shire North American Group INC | $27.03 | 2019 | |
| Genentech USA, INC. | $22.58 | 2019 | |
| Corium, LLC | $13.83 | 2023 | Azstarys |
| Arbor Pharmaceuticals, INC. | $13.40 | 2019 | |
| Glaxosmithkline, LLC. | $12.00 | 2019 | |
| Amarin Pharma, INC. | $11.65 | 2019 | |
| Allergan, INC. | $11.14 | 2019 | |
| Antares Pharma, INC. | $11.07 | 2019 | |
| Amgen INC. | $10.82 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Stone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.